Safety of maternal testosterone therapy during breast feeding

International Journal of Pharmaceutical Compounding

Volumn 13, Issue 4, 2009, Pages 314-317

  Glaser, Rebecca L ^a   Newman, Mark ^b   Parsons, Melanie ^c   Zava, David ^b   Glaser Garbrick, Daniel ^d  

^a WRIGHT STATE UNIVERSITY   (United States)

^b ZRT Laboratory   (United States)

^c Millennium Wellness Australia   (Australia)

^d Centerville High School   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE;

ADULT; ANDROGEN THERAPY; BREAST FEEDING; BREAST MILK; CASE REPORT; CONFERENCE PAPER; DRUG ABSORPTION; DRUG EXCRETION; FEMALE; HUMAN; INFANT; MATERNAL BLOOD; MORNING DOSAGE; TESTOSTERONE BLOOD LEVEL;

EID: 77949385555     PISSN: 10924221     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Burger HG, Hailes J, Menelaus M et al. The management of persistent menopausal symptoms with oestradiol-testosterone implants: Clinical, lipid and hormonal results. Maturitas 1984; 6(4): 351-358.
2. Brincat M, Magos A, Studd JW et al. Subcutaneous hormone implants for the control of climacteric symptoms. A prospective Study. Lancet 1984; 1(8367): 16-18.
3. Cardozo L, Gibb DM, Tuck SM et al. The effects of subcutaneous hormone implants during climacteric. Maturitas 1984; 5(3): 177-184.
4. Montgomery JC, Appleby L, Brincat M et al. Effect of oestrogen and testosterone implants on psychological disorders in the climacteric. Lancet 1987; 1(8528): 297-299.
5. Garnett T, Studd J, Watson N et al. A cross-sectional study of the effects of long-term percutaneous hormone replacement therapy on bone density. Obstet Gynecol 1991; 78(6): 1002-1007.
6. Dimitrakakis C, Jones RA, Liu A et al. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. Menopause 2004; 11(5): 531-535.
7. Berlin CM Jr. Sensitivity of the young infant to drug exposure through human milk. Adv Drug Deliv Rev 2003; 55(5): 678-693.
8. Fleishaker JC. Models and methods for predicting drug transfer into human milk. Adv Drug Deliv Rev 2003; 55(5): 643-652.
9. Ito S, Lee A. Drug excretion into breast milk: Overview. Adv Drug Deliv Rev 2003; 55(5): 617-627.
10. McManaman JL, Neville MC. Mammary physiology and milk secretion. Adv Drug Deliv Rev 2003; 55(5): 629-641.
11. Heinemann K, Ruebig A, Potthoff P et al. The Menopause Rating Scale (MRS) scale: A methodological review. Health Qual Life Outcomes 2004; 2: 45.
12. Kuhl H. Pharmacology of estrogens and progestogens: Influence of different routes of administration. Climacteric 2005; 8(Suppl 1): 3-63.
13. Glaser RL, Zava DT, Wurtzbacher D. Pilot study: Absorption and efficacy of multiple hormones delivered in a single cream applied to the mucous membranes of the labia and vagina. Gynecol Obstet Invest 2008; 66(2): 111-118.
14. Schiff I, Tulchinsky D, Ryan KJ. Vaginal absorption of estrone and 17beta-estradiol. Fertil Steril 1977; 28(10): 1063-1066.
15. Schiff I, Wentworth B, Koos B et al. Effect of estriol administration on the hypogonadal woman. Fertil Steril 1978; 30(3): 278-282.
16. Punnonen R, Vilska S, Grönroos M et al. The vaginal absorption of oestrogens in postmenopausal women. Maturitas 1980; 2(4): 321-326.
17. Heimer GM, Englund DE. Estriol: Absorption after long-term vaginal treatment and gastrointestinal absorption as influenced by a meal. Acta Obstet Gynecol Scand 1984; 63(6): 563-567.
18. Heimer GM, Englund DE. Plasma oestriol following vaginal administration: Morning versus evening insertion and influence of food. Maturitas 1986; 8(3): 239-243.
19. Mattsson LA, Cullberg G. Vaginal absorption of two estriol preparations. A comparative study in postmenopausal women. Acta Obstet Gynecol Scand 1983; 62(5): 393-396.
20. Cedars MI, Judd HL. Nonoral routes of estrogen administration. Obstet Gynecol Clin North Am 1987; 14(1): 269-298.
21. Carlström K, Pschera H, Lunell NO. Serum levels of oestrogens, progesterone, folliclestimulating hormone and sex-hormone-binding globulin during simultaneous vaginal administration of 17beta-oestradiol and progesterone in the pre- and post-menopause. Maturitas 1988; 10(4): 307-316.
22. Suh-Burgmann E, Sivret J, Duska LR et al. Long-term administration of intravaginal dehydroepiandrosterone on regression of low-grade cervical dysplasia - a pilot study. Gynecol Obstet Invest 2003; 55(1): 25-31.
23. Keller PJ, Riedmann R, Fischer M et al. Oestrogens, gonadotropins and prolactin after intra-vaginal administration of oestriol in post-menopausal women. Maturitas 1981; 3(1): 47-53.
24. Rigg LA, Hermann H, Yen SS. Absorption of estrogens from vaginal creams. N Engl J Med 1978; 298(4): 195-197.
25. Rosano G, Webb CM, Chierchia S et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Col Card 2000; 36(7): 2154-2159.
26. Oriba H, Bucks D, Maibach H. Percutaneous absorption of hydrocortisone and testosterone on the vulva and forearm: Effect of the menopause and site. Br J Derm 1996; 134: 229-233.
27. Thom M, Collins WP, Studd JW. Hormonal profiles in postmenopausal women after therapy in subcutaneous implants. Br J of Obstetrics and Gynaecology 1981; 88: 426-433.
28. Gambrell RD Jr, Natrajan PK. Moderate dosage estrogen-androgen therapy improves continuation rates in postmenopausal women: Impact of the WHI reports. Climacteric 2006; 9(3): 224-233.
29. Glaser R, Wurtzbacher D, Dimitrakakis C. Efficacy of testosterone therapy delivered by pellet implant. Maturitas 2009; 63(1): S73.